Description
30th Annual Heart Failure 2026: An Update on Therapy
Heart Failure 2026: An Update on Therapy delivers a comprehensive, clinically focused review of contemporary heart-failure prevention, diagnosis, and management. The program covers guideline-directed medical therapy, acute decompensated heart failure, cardiogenic shock, cardiomyopathies, genetic testing, device therapy, pulmonary hypertension, LVADs, transplantation, artificial intelligence, and emerging cardiovascular treatments.
About Heart Failure 2026
30th Annual Heart Failure 2026: An Update on Therapy continues a three-decade tradition of delivering clinically relevant updates on the prevention, diagnosis, and management of acute and chronic heart failure.
The curriculum combines expert lectures, case discussions, treatment updates, and interactive faculty sessions designed to help cardiovascular clinicians manage heart failure across a broad range of etiologies and clinical settings.
Major areas include guideline-directed medical therapy, HFrEF, HFpEF, acute decompensated heart failure, congestion, cardiogenic shock, chronic kidney disease, atrial fibrillation, hypertrophic cardiomyopathy, myocarditis, amyloidosis, pulmonary hypertension, genetic testing, device therapy, LVADs, transplantation, and artificial intelligence.
Why Choose Heart Failure 2026
âś“ Practical GDMT guidance for HFrEF, HFpEF, congestion, and cardiorenal disease
âś“ Advanced management strategies for cardiogenic shock, LVADs, and transplantation
âś“ Complex cardiomyopathy coverage including HCM, myocarditis, amyloidosis, and peripartum cardiomyopathy
âś“ Emerging therapies including gene therapy, stem-cell therapy, bio-omics, and AI
âś“ Expert-led case discussions focused on real-world clinical decision-making
âś“ Two full days of education organized across six scientific sessions
Clinical Areas Covered
Acute and Advanced Heart Failure: Acute Decompensated Heart Failure • Congestion • Cardiogenic Shock • Hemodynamic Classification • LVAD • Heart Transplantation
Cardiomyopathies: Hypertrophic Cardiomyopathy • Ischemic Cardiomyopathy • Peripartum Cardiomyopathy • Methamphetamine-Associated Cardiomyopathy • Myocarditis
Precision and Emerging Medicine: Genetic Testing • Gene Therapy • Stem-Cell Therapy • Bio-Omics • Artificial Intelligence
Associated Conditions: Chronic Kidney Disease • Atrial Fibrillation • Obesity • Pulmonary Hypertension • Amyloidosis • Fabry Disease • Recurrent Pericarditis
Learning Objectives
Symposium Leadership and Faculty
Symposium Leader: Uri Elkayam, MD, FACC
The faculty includes recognized experts in heart failure, cardiomyopathy, interventional cardiology, cardiovascular pharmacotherapy, genetics, pulmonary hypertension, mechanical circulatory support, and transplantation.
Complete Scientific Curriculum
Additional Program Content: case discussions and industry-supported, non-CME product-theatre sessions covering recurrent pericarditis, Fabry disease, and symptomatic obstructive hypertrophic cardiomyopathy.
Who Should Take Heart Failure 2026
This program is designed for clinicians involved in the prevention, diagnosis, and management of heart failure.
âś“ Cardiologists
âś“ Advanced Heart-Failure Specialists
âś“ Internists
âś“ Primary Care Physicians
âś“ Intensivists
âś“ Hospital-Based Clinicians
âś“ Pharmacists
âś“ Nurses
âś“ Advanced-Practice Providers
âś“ Cardiovascular Fellows and Other Healthcare Professionals
Course Package
🎥 Video Recordings
Continuous conference recordings covering the individual lectures and scientific sessions listed above.
đź’¬ VTT Subtitle Files
Subtitle files are included with the course package where available.
đź“„ PDF Resources
Supporting PDF resources and educational materials included in the available course files.
📦 Package Information
Video count: [ADD COUNT]
VTT count: [ADD COUNT]
PDF count: [ADD COUNT]
Total size: [ADD SIZE] GB
Important: Replace the package placeholders with the verified numbers of videos, VTT subtitle files, PDF resources, and the total file size before publishing this product.





Reviews
There are no reviews yet.